Abstract:Background Ischemia is a well-established contributor to vascular dementia. Indeed, the most common pathology in people with dementia is mixed, and over half of patients diagnosed with AD have demonstrable vascular pathologies. Ischemia induces an immune response which triggers secondary neurodegeneration remote to the initial lesion, and consequent cognitive decline. Ischemia-triggered vascular dementia is dependent on B-lymphocytes driving chronic neuroinflammation in adult mice. However, vascular dementia is most common in the aged, and there are key differences in inflammatory responses with age. Vascular cell adhesion molecule 1 (VCAM1) is an endothelial protein that facilitates vascular-immune crosstalk via interaction with very late antigen-4 (VLA-4). Soluble VCAM1 is elevated in stroke, vascular dementia, and normal aging in both people and mice. In aging mice, anti-VCAM1 ameliorates age-induced neuroinflammation and cognitive impairment. Although the mechanism is unclear, this is likely mediated via changes in endothelial cell activation and secretion of pro-inflammatory mediators. Therefore, we hypothesized that acute anti-VCAM1 treatment would reduce microgliosis and astrogliosis, while delayed treatment would reduce B and T lymphocyte infiltration in a mouse model of ischemia-triggered vascular dementia. Method Adult (3-month-old) or aged (10-month-old) C57BL/6J mice (n=10-15/group) underwent permanent distal middle cerebral artery occlusion. Mice were dosed with anti-VCAM1 antibody either 4 hours or 4 days post-ischemia, and then sacrificed at 72 hours, 3 weeks or 6 weeks post-ischemia. Microgliosis and astrogliosis were quantified as percent area immunostained in the lesion border by CD68 and GFAP, respectively. B and T cell infiltration were quantified as percent lesion immunostained by B220, and CD3+ cells in the ischemic lesion, respectively. Result Acute treatment reduced microgliosis 30% ( p=0.0476 ) and astrogliosis 39% (p<0.03). In adults, delayed anti-VCAM1 significantly reduced B and T cell infiltration approximately 25% ( p=0.0015 ) and 50% ( p=0.0192 ), respectively. Similarly, in aged mice, delayed anti-VCAM1 significantly reduced B and T cell infiltration approximately 50% ( p=0.0037 ) and 30% ( p=0.0036 ), respectively. In contrast, early anti-VCAM1 had little or no effect on B or T cell infiltration. Conclusion Together, these findings establish VCAM1 as a possible therapeutic target to ameliorate ischemia-induced neuroinflammation and consequent cognitive decline in a mouse model of vascular dementia.

VEGF-A in serum protects against memory impairment in APP/PS1 transgenic mice by blocking neutrophil infiltration

VEGF-induced Angiogenesis Ameliorates the Memory Impairment in APP Transgenic Mouse Model of Alzheimer’s Disease

Microglia prevent beta-amyloid plaque formation in the early stage of an Alzheimer’s disease mouse model with suppression of glymphatic clearance

Increased Plasma Levels of Macrophage Migration Inhibitory Factor in a Transgenic Mouse Model of Alzheimer’s Disease

Upregulation of MIF As a Defense Mechanism and a Biomarker of Alzheimer’s Disease

Vascular endothelial growth factor alleviates mitochondrial dysfunction and suppression of mitochondrial biogenesis in models of Alzheimer's disease

Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.

Self-assembling nanofibers alter the processing of amyloid precursor protein in a transgenic mouse model of Alzheimer's disease.

Valproic Acid Alleviates Memory Deficits and Attenuates Amyloid-β Deposition in Transgenic Mouse Model of Alzheimer’s Disease

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid‐β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Neutrophil adhesion in brain capillaries reduces cortical blood flow and impairs memory function in Alzheimer’s disease mouse models

Delivery of Exogenous Proteins by Mesenchymal Stem Cells Attenuates Early Memory Deficits in a Murine Model of Alzheimer's Disease.

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Analysis of Serum Β-Amyloid Peptides, Α2-Macroglobulin, Complement Factor H, and Clusterin Levels in APP/PS1 Transgenic Mice During Progression of Alzheimer's Disease.

Angiotensin-(1–7) Analogue AVE0991 Modulates Astrocyte-Mediated Neuroinflammation via lncRNA SNHG14/miR-223-3p/NLRP3 Pathway and Offers Neuroprotection in a Transgenic Mouse Model of Alzheimer’s Disease

Targeting VCAM1 to reduce neuroinflammation in ischemia‐triggered vascular dementia

Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease

Vascular oxidative stress causes neutrophil arrest in brain capillaries, leading to decreased cerebral blood flow and contributing to memory impairment in a mouse model of Alzheimerâ€™s disease

NeuroProtect, a Candidate Formula From Traditional Chinese Medicine, Attenuates Amyloid-β and Restores Synaptic Structures in APP/PS1 Transgenic Mice

Natural Killer Cells Improve Cognitive Function and Support to Induce Amyloid Beta Clearance by Functional Recovery of Impaired Microglia in Natural Killer Cell‐treated Alzheimer’s Diseases Mouse Model